Hjem › Diffust stort B-celle lymfom › Utah
Diffust stort B-celle lymfom kliniske forsøg i Utah
14 studier for Diffust stort B-celle lymfom søger deltagere på steder i Utah.
Byer i Utah
Officiel studietekst (engelsk)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- Intermountain Health LDS Hospital, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06500273A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Community Cancer Trials of Utah, Ogden
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06091865A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Intermountain Medical Center ( Site 0182), Murray
- Intermountain Healthcare - St. George ( Site 0203), St. George
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Intermountain Healthcare, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
- Huntsman Cancer Institute, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT06227026Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. jul. 2026 · NCT05077527External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
- Huntsman Cancer Institute at University of Utah, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT07528352A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04830137Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Huntsman Cancer Institute, University of Utah, Salt Lake City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT04775745Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. okt. 2025 · NCT05890352Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 26. sep. 2024 · NCT06238648Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.